JP6215713B2 - 有害臨床転帰のリスクを予測する方法 - Google Patents

有害臨床転帰のリスクを予測する方法 Download PDF

Info

Publication number
JP6215713B2
JP6215713B2 JP2013558218A JP2013558218A JP6215713B2 JP 6215713 B2 JP6215713 B2 JP 6215713B2 JP 2013558218 A JP2013558218 A JP 2013558218A JP 2013558218 A JP2013558218 A JP 2013558218A JP 6215713 B2 JP6215713 B2 JP 6215713B2
Authority
JP
Japan
Prior art keywords
galectin
level
subject
soluble
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013558218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014514536A (ja
JP2014514536A5 (enExample
Inventor
ジェームス ブイ． スナイダー
ジェームス ブイ． スナイダー
Original Assignee
クリティカル ケア ダイアグノスティクス インコーポレイテッド
クリティカル ケア ダイアグノスティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリティカル ケア ダイアグノスティクス インコーポレイテッド, クリティカル ケア ダイアグノスティクス インコーポレイテッド filed Critical クリティカル ケア ダイアグノスティクス インコーポレイテッド
Publication of JP2014514536A publication Critical patent/JP2014514536A/ja
Publication of JP2014514536A5 publication Critical patent/JP2014514536A5/ja
Application granted granted Critical
Publication of JP6215713B2 publication Critical patent/JP6215713B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013558218A 2011-03-17 2012-03-16 有害臨床転帰のリスクを予測する方法 Expired - Fee Related JP6215713B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453782P 2011-03-17 2011-03-17
US61/453,782 2011-03-17
PCT/US2012/029500 WO2012141844A2 (en) 2011-03-17 2012-03-16 Methods predicting risk of an adverse clinical outcome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017181201A Division JP2018021926A (ja) 2011-03-17 2017-09-21 有害臨床転帰のリスクを予測する方法

Publications (3)

Publication Number Publication Date
JP2014514536A JP2014514536A (ja) 2014-06-19
JP2014514536A5 JP2014514536A5 (enExample) 2015-04-30
JP6215713B2 true JP6215713B2 (ja) 2017-10-18

Family

ID=47009907

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013558218A Expired - Fee Related JP6215713B2 (ja) 2011-03-17 2012-03-16 有害臨床転帰のリスクを予測する方法
JP2017181201A Pending JP2018021926A (ja) 2011-03-17 2017-09-21 有害臨床転帰のリスクを予測する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017181201A Pending JP2018021926A (ja) 2011-03-17 2017-09-21 有害臨床転帰のリスクを予測する方法

Country Status (6)

Country Link
US (4) US8728742B2 (enExample)
EP (2) EP2686689B1 (enExample)
JP (2) JP6215713B2 (enExample)
CN (2) CN103718046B (enExample)
ES (2) ES2750126T3 (enExample)
WO (1) WO2012141844A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
ES2529618T3 (es) 2006-04-24 2015-02-23 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de enfermedades graves
EP2021799B1 (en) * 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
ES2566169T3 (es) 2006-05-01 2016-04-11 Critical Care Diagnostics, Inc. Diagnóstico de enfermedad cardiovascular
HUE025058T2 (en) * 2006-05-02 2016-01-28 Critical Care Diagnostics Inc Differential diagnosis of pulmonary and cardiovascular disease
DK2660599T3 (en) 2008-04-18 2014-12-08 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
ES2859577T3 (es) 2010-04-09 2021-10-04 Critical Care Diagnostics Inc Anticuerpos contra ST-2 humana soluble y ensayos
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
CA2842072A1 (en) 2011-07-18 2013-01-24 James V. Snider Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
HK1208624A1 (en) 2012-05-18 2016-03-11 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
SG10201704311VA (en) 2012-08-16 2017-07-28 Critical Care Diagnostics Inc Methods for predicting risk of developing hypertension
HK1212057A1 (en) 2012-08-21 2016-06-03 重症监护诊断股份有限公司 Multimarker risk stratification
CN104521298B (zh) * 2013-08-08 2018-07-03 华为技术有限公司 传输信号的方法、网络侧设备和用户设备
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US20210223264A1 (en) * 2016-04-25 2021-07-22 Siemens Healthcare Diagnostics Inc. Diagnostic method(s) for detecting and treating post-infarct myocardium remodeling and diffuse myocardial fibrosis
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
RU2677611C1 (ru) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN113425271B (zh) * 2021-05-20 2024-02-06 上海小芃科技有限公司 日间手术出院判断方法、装置、设备及存储介质
WO2024092136A2 (en) * 2022-10-28 2024-05-02 Memorial Sloan-Kettering Cancer Center Machine learning modeling for inpatient prediction

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
EP2305235A1 (en) 1997-04-02 2011-04-06 The Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
EP0988552B1 (en) 1997-06-10 2010-11-24 Lpath, Inc. Methods for early detection of heart disease
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
WO2000035473A2 (en) 1998-12-18 2000-06-22 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
WO2000062076A1 (en) 1999-04-13 2000-10-19 Hsu Daniel K Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (en) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
IL149251A0 (en) 2000-08-22 2002-11-10 Brigham & Womens Hospital Diagnosis and treatment of cardiovascular conditions
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030004132A1 (en) 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
US20070042978A1 (en) 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
WO2004111654A2 (en) * 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
EP1522857A1 (en) 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US20060257558A1 (en) 2003-10-31 2006-11-16 Hiroshi Nomura Plasma polymerization of atomically modified surfaces
CA2921196C (en) 2003-11-26 2019-03-05 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
ES2529618T3 (es) * 2006-04-24 2015-02-23 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de enfermedades graves
EP2021799B1 (en) 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
ES2566169T3 (es) 2006-05-01 2016-04-11 Critical Care Diagnostics, Inc. Diagnóstico de enfermedad cardiovascular
HUE025058T2 (en) 2006-05-02 2016-01-28 Critical Care Diagnostics Inc Differential diagnosis of pulmonary and cardiovascular disease
WO2007130627A2 (en) 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
CA2720614A1 (en) * 2008-04-07 2009-10-15 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
DK2660599T3 (en) * 2008-04-18 2014-12-08 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
JP2011528115A (ja) * 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル
BRPI0919975A2 (pt) * 2008-10-29 2015-12-15 Bg Medicine Inc imunoensaio para galectina-3
ES2859577T3 (es) 2010-04-09 2021-10-04 Critical Care Diagnostics Inc Anticuerpos contra ST-2 humana soluble y ensayos
CN103718046B (zh) 2011-03-17 2016-10-12 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
CA2842072A1 (en) 2011-07-18 2013-01-24 James V. Snider Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
HK1208624A1 (en) 2012-05-18 2016-03-11 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
SG10201704311VA (en) 2012-08-16 2017-07-28 Critical Care Diagnostics Inc Methods for predicting risk of developing hypertension
HK1212057A1 (en) 2012-08-21 2016-06-03 重症监护诊断股份有限公司 Multimarker risk stratification
MX2016009060A (es) 2014-01-10 2016-09-09 Critical Care Diagnostics Inc Metodos y sistemas para determinar el riesgo de falla cardiaca.
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
US20120276551A1 (en) 2012-11-01
US8728742B2 (en) 2014-05-20
EP3605104B1 (en) 2021-09-15
WO2012141844A2 (en) 2012-10-18
US9239333B2 (en) 2016-01-19
ES2750126T3 (es) 2020-03-25
JP2014514536A (ja) 2014-06-19
EP3605104A1 (en) 2020-02-05
US20160299153A1 (en) 2016-10-13
US9823257B2 (en) 2017-11-21
CN103718046A (zh) 2014-04-09
WO2012141844A3 (en) 2013-03-21
CN106940375A (zh) 2017-07-11
US10393756B2 (en) 2019-08-27
EP2686689A4 (en) 2014-09-03
JP2018021926A (ja) 2018-02-08
US20180292415A1 (en) 2018-10-11
CN106940375B (zh) 2019-03-08
CN103718046B (zh) 2016-10-12
ES2897419T3 (es) 2022-03-01
US20140234875A1 (en) 2014-08-21
EP2686689A2 (en) 2014-01-22
EP2686689B1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
US10393756B2 (en) Methods of treating a subject having heart failure that include detecting levels of galectin-3 and soluble ST2
JP6788050B2 (ja) 主要有害心イベントのリスクを予測する方法
EP2021799B1 (en) Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
JP6757757B2 (ja) 高血圧症を発症するリスクを予測するための方法
DK2482078T3 (en) Cardiovascular disease diagnosis
Ahn et al. Serum leucine-rich α2-glycoprotein is elevated in patients with systemic lupus erythematosus and correlates with disease activity
HK1192619A (en) Methods predicting risk of an adverse clinical outcome
HK1192619B (en) Methods predicting risk of an adverse clinical outcome
Jan et al. Research Article Associates of an Elevated Natriuretic Peptide Level in Stable Heart Failure Patients: Implications for Targeted Management
HK1212022B (en) Methods for predicting risk of developing hypertension

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150313

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170921

R150 Certificate of patent or registration of utility model

Ref document number: 6215713

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees